Regeneron reports fourth quarter and full year 2021 financial and operating results

Tarrytown, n.y., feb. 4, 2022 /prnewswire/ -- fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to regen-cov ® (2); revenues excluding regen-cov(1) increased 17% full year 2021 revenues increased 89% to $16.07 billion compared to full year 2020 including $6.19 billion attributable to regen-cov (2); revenues excluding regen-cov (1) increased 19% fourth quarter 2021 eylea® u.s. net sales increased 15% to $1.55 billion versus fourth quarter 2020 and full year 2021 eylea u.s. net sales increased 17% versus 2020 fourth quarter 2021 dupixent® global net sales (3), which are recorded by sanofi, increased 51% to $1.77 billion versus fourth quarter 2020 and full year 2021 dupixent global net sales increased 53% versus 2020 fourth quarter 2021 gaap diluted eps was $19.69 and non-gaap diluted eps (1) was $23.72 regeneron pharmaceuticals, inc. (nasdaq: regn) today announced financial results for the fourth quarter and full year 2021 and provided a business update.
REGN Ratings Summary
REGN Quant Ranking